- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SEC launches probe of ADAC financials
ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the company’s
ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the companys restatement.
News of the probe came out in ADACs annual 10-K report, filed with the SEC on Jan. 3. In the filing, ADAC stated that it is cooperating with the regulatory agency and that it cannot predict the outcome of the investigation.
In December 1998, ADAC announced that it would restate its financial results for the previous three years, provoking dramatic selling of its stock and shareholder lawsuits (SCAN 1/13/99). ADAC is contesting the suits, which were consolidated in April of last year.
In other ADAC news, the companys HealthCare Information Systems (HCIS) division and Agfa have signed an OEM agreement under which ADAC will distribute Agfas ADC computed radiography systems and Drystar hardcopy printers with its Envoi RIS and PACS systems. The deal is part of ADACs effort to offer a comprehensive RIS/PACS product to its customers, according to the Milpitas, CA-based company.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
